PinnyPeptide

ACTH 1-39 (Corticotropin) vs PNC-27

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

ACTH 1-39 (Corticotropin)

Cognitive

Full-length adrenocorticotropic hormone — endocrine research peptide, melanocortin agonist.

Peptide B

PNC-27

Research

Membrane-active anticancer research peptide — selectively lyses cancer cell membranes.

Typical vial

5 mg

Typical dose

250 (diagnostic) mcg

Half-life

~10-15 minutes (plasma)

FDA status

Cosyntropin (ACTH 1-24) FDA approved as Cortrosyn. Repositor…

Typical vial

5 mg

Typical dose

Research-only mcg

Half-life

Variable

FDA status

Not FDA approved.

ACTH 1-39 (Corticotropin) effects

  • Stimulates adrenal cortex to release cortisol
  • Activates MC2R on adrenocortical cells (primary)
  • Secondary activation of MC1R (pigmentation), MC3-5R
  • Used diagnostically to assess adrenal function
  • Anti-inflammatory effects via cortisol release

PNC-27 effects

  • Selective cancer cell membrane lysis
  • Activity across broad range of cancer cell types in vitro
  • Mechanism involves cancer-cell HDM-2 surface expression
  • Direct tumoricidal effect (not cytostatic)
  • Sparing of normal cells in preclinical models

ACTH 1-39 (Corticotropin) side effects

  • All side effects of pharmacological hypercortisolism: hyperglycemia, weight gain, mood changes, immunosuppression, hypertension
  • Hyperpigmentation with chronic use (MC1R activation)
  • HPA axis suppression with prolonged dosing
  • Acne, fluid retention
  • Adrenal hyperplasia with chronic stimulation

PNC-27 side effects

  • Essentially uncharacterized in humans
  • Theoretical: off-target membrane effects on stressed normal cells
  • Injection-site reactions
  • Possible inflammatory response from rapid cancer-cell lysis
  • Long-term safety unstudied

ACTH 1-39 (Corticotropin) dosing ranges

Adrenal stimulation test (clinical)

250 mcg · Single IV or IM dose · Diagnostic, one-time

Endocrine research

Variable · Per study protocol · Per study protocol

PNC-27 dosing ranges

In vitro / animal cancer research

Variable per protocol · Per study design · Per protocol

Human self-experimentation

Not recommended · — · —

ACTH 1-39 (Corticotropin) vs PNC-27 — common questions

What is the difference between ACTH 1-39 (Corticotropin) and PNC-27?

ACTH 1-39 (Corticotropin): Full-length adrenocorticotropic hormone — endocrine research peptide, melanocortin agonist. Typical dose 250 (diagnostic) mcg. PNC-27: Membrane-active anticancer research peptide — selectively lyses cancer cell membranes. Typical dose Research-only mcg. Both fall under the Cognitive and Research categories.

Can you stack ACTH 1-39 (Corticotropin) and PNC-27?

Stacking ACTH 1-39 (Corticotropin) with PNC-27 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, ACTH 1-39 (Corticotropin) or PNC-27?

ACTH 1-39 (Corticotropin) is typically dosed: Single IV or IM dose for Adrenal stimulation test (clinical); Per study protocol for Endocrine research. PNC-27 is typically dosed: Per study design for In vitro / animal cancer research; — for Human self-experimentation.

Are ACTH 1-39 (Corticotropin) and PNC-27 FDA approved?

ACTH 1-39 (Corticotropin): Cosyntropin (ACTH 1-24) FDA approved as Cortrosyn. Repository ACTH (porcine, full-length) FDA approved as Acthar Gel for infantile spasms, MS exacerbations, and other indications. PNC-27: Not FDA approved.

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free